Call for Pilot Research Grant Applications - CLOSED!
Alzheimer’s Disease Research Center (5-1-10 to 4-30-15):
Novel protein biomarkers for Alzheimer’s disease in cerebrospinal fluid
Changing tau protein levels and tau protein isoforms in mouse models of dementia
APOE metabolism in AD and controls
Healthy Aging & Senile Dementia Program Project (5-15-09 to 12-31-13):
Project 1 Preclinical AD predicts poststroke dementia
John C. Morris, MD
Project 2 Antecedent biomarkers of AD in CSF and plasma
David Holtzman, MD
Project 3 Markers for DAT: Control, variability, and personality
David Balota, Ph.D.
Project 4 Sequence variation in genes for biomarker proteins and age at onset
Alison Goate, DPhil
5/13 - 4/14
Preclinical imaging of tau pathology with the novel PET imaging agent [F-18]T807
McConathy, Jonathan, MD, PhD
Circadian regulation of amyloid-β clearance
Musiek, Erik, MD, PhD
TREM2 as a key player and a potential biomarker in Alzheimer’s disease
Piccio, Laura, MD, PhD
5/12 - 4/13
How do TREM2 mutations promote susceptibility to Alzheimer Disease?
Colonna, Marco, MD
Role of GGGGCC expansion sizes in C9ORF72 dementia and ALS patients
Harms, Mathew, MD
Modulation of CSF Aβ Through Pharmacological and Behavioral Manipulation of Sleep
Lucey, Brendan, MD
5/11 - 4/12
Lens opacities as predictors of Alzheimer disease
Beebe, David C., PhD, FARVO
Plasma microRNA biomarkers for early detection of Alzheimer’s disease
Kim, Jungsu, PhD
Driving performance in preclinical Alzheimer’s disease
Roe, Catherine, PhD
5/10 - 4/11
Effect of endogenous amyloid-ß on synaptic plasticity in vivo.
John R. Cirrito, PhD
Risk of falls in preclinical Alzheimer's disease: a prospective study.
Susan L. Stark, PhD
Selective PET tracers for human Cerebral Amyloid Angiopathy.
Gregory J. Zipfel
Funded through gift funds:
Selective labels for tau fibrils.
Marc I. Diamond, MD
5/09 - 4/10
Interaction Between HIV and Aging Using 11C-labeled Pittsburgh Compound-B (11C-PIB)
Role of TOR3A as a regulator of Aß production.
Developing antisense oligonucleotides to modify tau in mouse models of dementia.
5/08 - 4/09
Axonal Transport of APP: The Role of the Mixed Lineage Kinase DLK
Proteasomal Impairment by Mutant Ubiquitin and Enhanced Toxicity of Aggregates
Mishandling of protein aggregates in p97/VCP associated fronto-temporal dementia.
Funded through gift funds:
Analysis of beta secretase activity and APP processing in GGA knockout mice.
5/07 - 4/08
PET Agent for Imaging of P-glycoprotein (Pgp) mediated transport activity in Alzheimer’s disease.
Vijay Sharma, Radiology
Neurology and Radiology, Use of 11C-PIB to determine risk of recurrence of lobar intracerebral hemorrhage: A pilot study.
Roles of Aßtype lamins on telomere metabolism and premature aging.
5/06 - 4/07
Eye movements during visual search in healthy aging and very mild DAT
Richard A. Abrams, PhD
Emotional Aging: Preservation of Function in the Elderly and Alzheimer's Patients
Randy J. Larsen, PhD
Selective synapse loss and ß-amyloid deposition in the Tg2576 mouse
Hongxin Dong, MD PhD
5/05 - 4/06:
Genetic Factors Modulating Quantitative Traits in LOAD
Anthony Hinrichs, Psychiatry
Metabolic Consequences of PINK 1 Mutations
Paul Kotzbauer, Neurology
Prospective Memory in DAT and APOE Genotype
Mark McDaniel, Psychology
PK11195 PET imaging of inflammation in aging and DAT
Mark Mintun, Director of Center for Clinical Imaging Research
Mutant Valosin-Containing Protein Causes Neurodegeneration and Frontotemporal Dementia
Nigel Cairns, Neurology